I. Introduction -
No pharmaceutical antitrust decision has had more impact than the Supreme Court’s 2013 decision in Federal Trade Commission v. Actavis, a decision which officially defined the term “reverse payment...more
10/11/2023
/ Abbreviated New Drug Application (ANDA) ,
Anti-Competitive ,
Antitrust Litigation ,
AstraZeneca ,
Causation ,
Food and Drug Administration (FDA) ,
FTC v Actavis ,
Generic Drugs ,
Hatch-Waxman ,
Motion to Dismiss ,
Orange Book ,
Pharmaceutical Industry ,
Popular ,
RanBaxy ,
Reverse Payment Settlement Agreements ,
SCOTUS ,
Settlement
In the world of technology, Standard Setting Organizations (“SSOs”) play a crucial role in helping to facilitate innovation. They do so by creating industry standards that ensure quality and promote and enable the development...more
On Tuesday, August 11, 2020, the Ninth Circuit reversed and vacated Judge Lucy Koh’s controversial, post-bench trial decision in FTC v. Qualcomm Inc., 411 F. Supp. 3d 658 (N.D. Cal. 2019), regarding whether Qualcomm violated...more
8/17/2020
/ Anticompetitive Behavior ,
Antitrust Violations ,
Appeals ,
Cell Phones ,
Federal Trade Commission (FTC) ,
FRAND ,
FTC Act ,
Injunctive Relief ,
Intellectual Property Protection ,
IP License ,
Monopolization ,
OEM ,
Patent Royalties ,
Popular ,
Qualcomm ,
Remand ,
Reversal ,
Sherman Act ,
Standard Essential Patents
On July 8, 2020, Judge Alison Burroughs granted-in-part Defendants Shire and Actavis’s motion to decertify a direct purchaser plaintiff class in an alleged reverse payment antitrust case pending in the Federal District Court...more
7/13/2020
/ Antitrust Violations ,
Chapter 11 ,
Class Action ,
Class Certification ,
Class Representatives ,
Commercial Bankruptcy ,
Conflicts of Interest ,
Decertification ,
Defense Strategies ,
Direct Purchasers ,
Disqualified Persons ,
Pharmaceutical Industry ,
Popular ,
Wholesale